VJHemOnc is committed to improving our service to you

ICML 2019 | CheckMate 205 study of nivo plus AVD in cHL: 2-year follow-up

VJHemOnc is committed to improving our service to you

Stephen Ansell

Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, gives an update on the 2-year follow-up of cohort D of the CheckMate 205 study (NCT02181738), which investigated pembrolizumab for the treatment of classical Hodgkin lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter